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Abstract. Germline mutations in the human breast cancer 
genes BRCA1 and BRCA2 account for a substantial propor-
tion of familial, early-onset breast and ovarian cancers. The 
present study reports a novel disease-causing BRCA1 muta-
tion, nucleotide 3020insCT/c.2901insCT, in a 55-year-old 
Spanish female with breast and ovarian cancer. This frame-
shift mutation creates a premature stop codon at amino acid 
1000, leading to a truncated BRCA1 protein. To the best of our 
knowledge, this mutation has not been previously described 
in the Breast Cancer Information Core (BIC) database or the 
published literature. 
Introduction
Hereditary breast and ovarian cancer (HBOC) is an autosomal 
dominant syndrome with incomplete penetrance. The two 
most commonly mutated genes in HBOC are BRCA1 and 
BRCA2, which are essential components of the double-strand 
break repair system (1). Almost 3,500 cancer-associated muta-
tions, scattered throughout the two genes, have so far been 
reported in the Breast Cancer Information Core (BIC) database 
(http://research.nhgri.nih.gov/bic/). The present study reports 
a new germline nucleotide 3020insCT/c.2901insCT mutation 
detected in the BRCA1 gene. In general, germline mutations 
in known breast cancer risk genes account for ~20% of breast 
cancers associated with a family history. It is therefore crucial 
to identify these individuals to offer appropriate cancer 
management and understand the contribution of BRCA1 and 
BRCA2 mutation-associated risks.
Case report
A 55-year-old non-Ashkenazi Spanish female diagnosed with 
breast cancer (at 51 years old) and ovarian cancer (at 55 years 
old) and treated at the University Clinic of Navarra (CUN; 
Pamplona, Navarra, Spain), was transferred to the genetic 
counseling unit. The clinical history of the patient lead us 
to consider the possibility of HBOC syndrome. Following 
verbal and written informed consent, genomic DNA was 
extracted from a peripheral blood sample and the BRCA1 
and BRCA2 genes were sequenced on an automated analyzer 
(ABI PRISM® 3130XL; Applied Biosystems, Foster City, CA, 
USA). The results were compared to the consensus wild-type 
sequences (Genbank NM_007294.2 for BRCA1 and Genbank 
NM_000059.1 for BRCA2). A 3020insCT/c.2901insCT 
frameshift mutation was identified in exon 11 of BRCA1 
(Fig. 1). The insertion was confirmed by repeated analyses 
including reverse-primer sequencing. A BRCA1-Multiplex 
Ligation-dependent Probe Amplification (MLPA) analysis 
was performed, in order to investigate whether the mutation 
was able to lead to an exon rearrangement. The results indi-
cated that none of the BRCA1 alleles showed deletion and/or 
duplication (results not shown). 
Genetic analysis was recommended to the only other indi-
vidual at risk in patient's family, namely the twin sister, and the 
analysis showed that she did not carry the mutation.
Discussion
A 3020insCT/c.2901insCT frameshift mutation in exon 11 
of the BRCA1, which has yet to be reported in the BIC data-
base, was detected in a 55-year-old non-Ashkenazi Spanish 
female diagnosed with breast and ovarian cancer. Since other 
family members were not available for genetic analysis, the 
segregation of the mutation could not be established. From 
the literature available, it may be deduced that the muta-
tion leads to the deletion of the coiled-coil domain and 
BRCA1 C terminus (BRCT) domains of the BRCA1 protein. 
The coiled-coil region is critical for transcriptional activation 
through its interaction with the basic leucine zipper (bZIP) 
domain of the JunB protein. In vitro and in vivo experiments 
suggest that this BRCA1-JunB interaction is particularly 
important for the suppression of ovarian cancer (2). The lack 
of the coiled-coil domain in the present patient may have 
been closely correlated with the development of the ovarian 
cancer. However, BRCA1 has a pivotal function within the 
BRCA1-associated genome surveillance complex through the 
coordination of the actions of damage-sensing and executive 
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repair proteins. Solyom et al (3) showed that the Abraxas 
protein serves as a central organizer of a large BRCA1 holoen-
zyme complex. Abraxas directly binds, via its phosphorylated 
C terminus, to the BRCA1 BRCT motifs, linking BRCA1 to a 
core protein complex dedicated to ubiquitin chain recognition 
and hydrolysis at DNA double-strand breaks (3,4). Moreover, 
BRCT domains in BRCA1 are able to bind DNA strand breaks 
and ends in vitro, which is enhanced by the formation of the 
BRCA1-BARD1 heterodimer (5). The structural studies of 
Kobayashi et al showed that the BRCT domain partially inserts 
into the major groove and makes extensive contacts with the 
DNA backbone (6), suggesting the possibility that proteins 
with BRCT domains may act as DNA sensors and transducers 
of DNA damage response signaling. The mutation identified 
in the present study would markedly compromise these func-
tions, with profound biological consequences. The premature 
stop codon at amino acid 1000 leads to a truncated protein that 
has 70% of its normal length. The advantage of having mutant 
BRCA1 human breast cancer cell lines is that the impact of 
pathogenic human mutations may be evaluated in the context 
of a human genetic background. A previous study of 41 human 
breast cancer cell lines identified a BRCA1 mutant cell line, 
SUM149PT, with a nucleotide deletion at position 2288 (7). 
The resulting truncated BRCA1 protein lacked the C-terminal 
BRCT and coiled-coil domains similar to the present patient. 
Nuclear BRCA1 protein expression was not detectable in the 
cell line, therefore corroborating the tumor suppressor func-
tion of BRCA1 and the pathogenicity of the mutation. 
The next step was to search for bibliographic evidence of 
the present mutation in BRCA1‑knockout animal models. The 
homozygous loss of BRCA1 generally leads to early embry-
onic lethality, although it is possible to extend the viability 
though the removal of p53 function. Among the range of 
models available, McCarthy et al designed truncated human 
BRCA1f22-24/p53+/- mice (harboring the second BRCT 
domain), that develop estrogen receptor-negative (ER-) and 
progesterone receptor-negative (PR-) tumors lacking HER2 
protein overexpression and gene amplification (8). This 
phenotype is similar to 64-90% of human BRCA1-mutation 
breast cancers, so called ‘triple negative’ breast cancers. The 
immunophenotypic features of the present patient's tumor 
indicated a noticeably different pattern, being ER+, PR+ and 
ErbB2-negative. It has been reported that 10-36% of BRCA1 
mutation-related invasive breast cancers are, in fact, ER+. 
Furthermore, BRCA1 mutation carriers who are older or post-
menopausal at the time of the diagnosis of breast cancer are 
more likely to have an ER+ breast cancer (9,10). With regard to 
the origin of these ER+ BRCA1-related breast cancers, Lim et al 
observed the expansion of a committed luminal progenitor 
population, containing ER+ and ER- cells, in preneoplastic 
tissues of BRCA1 mutation carriers and proposed the luminal 
progenitor cells as the cell of origin for BRCA1-associated 
cancers (11). In mouse models with the deletion of BRCA1, 
the expression of ER in the resulting tumors appears to 
depend on whether BRCA1 is deleted at an earlier or later 
stage of cell differentiation (12-14). These studies suggest that 
BRCA1‑deficient ER+ tumors may derive from BRCA1 loss in 
an ER+ luminal progenitor cell.
Another key point is the therapeutic approach for ER+ 
BRCA1-associated breast cancers. Given the availability 
of effective therapies that exploit defects in homologous 
recombination, such as PARP-1 inhibitors and cisplatin, it is 
increasingly important to determine whether these therapies 
are likely to be effective in ER+ BRCA1-mutant cancers. A 
recent study by Kaplan et al indicated that ER+ BRCA1-related 
breast cancers are indistinguishable from ER- BRCA1-related 
cancers in their nuclear expression of PARP-1, suggesting that 
ER+ BRCA1-related breast cancers may respond well to drugs 
that exploit BRCA1 deficiency (15). ER+ BRCA1-related breast 
cancers appear to be a unique group and efforts should be 
made to identify the individuals for whom estrogen-modifying 
agents are likely to be particularly effective.
Acknowledgements
The authors are grateful to all patients and their families.
Figure 1. Chromatogram of breast cancer (BRCA)1 exon 11 showing the 3020insCT/c.2901insCT in the heterozygous state (arrow) in the peripheral blood of 
the patient.
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